Dedicated to Developing Novel Medicines for CNS Diseases

About Us

Committed to Advancing a New Generation of Oral Antidepressants

AV-101, an NMDA receptor glycine-binding site antagonist, is a new generation oral antidepressant drug candidate in Phase 2 development, inspired by breakthrough clinical studies involving ketamine. The mechanism of action of AV-101, and that of ketamine, is fundamentally differentiated from all FDA-approved antidepressants.

VistaGen Therapeutics, Inc. Pipeline
What Makes AV-101 Different?

Going Above and Beyond Current Treatment Options

Focused on providing novel solutions for millions of drug-treated depression patients with inadequate response to current depression therapies.

Learn More About Ketamine and AV-101

Backed by an Experienced Leadership Team

Our highly experienced management team, board of directors and clinical and regulatory advisory board have a proven track record of developing innovative drugs to treat CNS diseases.

Meet Our Team

Stock Information

View Detailed Stock Info
Day Range
52 Week Range

Corporate Presentation

For Investors

Email Updates

Be the first to receive news, events & updates Sign Up